Optiscan Imaging Ltd (ASX: OIL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Optiscan Imaging Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $99.20 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.04 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -10.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Optiscan Imaging Ltd (ASX: OIL)
    Latest News

    A drawing of a white rocket streaking up, indicating a surging share pirce movement
    Share Market News

    Why the OptiScan (ASX:OIL) share price is rocketing 26% today

    The OptiScan Imaging Limited (ASX: OIL) share price is rocketing 26% after announcing the appointment of a experienced industry executive.

    Read more »

    research with microscope
    Share Market News

    Why the Optiscan (ASX:OIL) share price is going gangbusters

    The Optiscan share price is flying today as the company announced the next stage of its breast cancer study.

    Read more »

    Share Market News

    Why the OptiScan (ASX:OIL) share price is climbing higher

    The Optiscan Imaging Ltd (ASX: OIL) share price is up 4.35% today after a positive announcement on a product order.

    Read more »

    woman looking up as if watching asx share price
    Share Market News

    Optiscan (ASX:OIL) share price flat on FDA update

    The Optiscan Imaging Limited (ASX: OIL) share price is flat today despite FDA advice. Let's look at what's ahead for…

    Read more »

    OIL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Optiscan Imaging Ltd

    Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States.

    OIL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    15 Jan 2026 $0.10 $0.01 11.11% 9,126 $0.09 $0.10 $0.09
    13 Jan 2026 $0.09 $-0.01 -10.10% 102,025 $0.10 $0.10 $0.09
    12 Jan 2026 $0.10 $0.01 10.64% 182,587 $0.09 $0.10 $0.09
    09 Jan 2026 $0.09 $0.00 0.00% 116,156 $0.09 $0.09 $0.09
    08 Jan 2026 $0.09 $0.00 0.00% 1,539 $0.09 $0.09 $0.09
    07 Jan 2026 $0.09 $0.00 0.00% 154,664 $0.10 $0.10 $0.09
    06 Jan 2026 $0.10 $0.00 0.00% 9,054 $0.10 $0.10 $0.10
    05 Jan 2026 $0.10 $0.00 0.00% 285,198 $0.11 $0.11 $0.10
    02 Jan 2026 $0.10 $0.00 0.00% 52,720 $0.10 $0.10 $0.10
    31 Dec 2025 $0.10 $0.00 0.00% 16,953 $0.10 $0.10 $0.10
    30 Dec 2025 $0.10 $0.00 0.00% 251 $0.10 $0.10 $0.10
    29 Dec 2025 $0.10 $0.00 0.00% 269,727 $0.11 $0.11 $0.10
    24 Dec 2025 $0.11 $0.00 0.00% 104,856 $0.11 $0.11 $0.11
    23 Dec 2025 $0.10 $0.00 0.00% 94,981 $0.10 $0.10 $0.10
    22 Dec 2025 $0.11 $0.00 0.00% 165,768 $0.11 $0.11 $0.11
    19 Dec 2025 $0.11 $0.01 10.20% 84,913 $0.10 $0.11 $0.10
    18 Dec 2025 $0.10 $-0.01 -9.52% 240,260 $0.10 $0.10 $0.10

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Dec 2025 Karen Borg Transfer 210,365 $17,881
    Off-market transfer. As per announcement on 29-12-2025
    26 Sep 2025 Robert Cooke Buy 72,500 $6,101
    On-market trade.
    23 Sep 2025 Karen Borg Issued 24,929 $2,118
    Rights issue.
    23 Sep 2025 Karen Borg Transfer 99,716 $8,076
    Off-market transfer. Assuming off market transfer of shares
    23 Sep 2025 Karen Borg Transfer 99,716 $8,076
    Off-market transfer. Assuming off market transfer of shares
    23 Sep 2025 Ronnie (Ron) Song Issued 250,000 $21,250
    Rights issue.
    23 Sep 2025 Camile Farah Issued 235,294 $20,000
    Rights issue.
    21 Mar 2025 Camile Farah Buy 12,984 $1,555
    On-market trade.
    17 Mar 2025 Camile Farah Buy 195,385 $23,474
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ronnie (Ron) Song Non-Executive Director Feb 2021
    Mr Song had a 25-year business career in Australia before being headhunted in 1999 to assist in expanding a multi-franchise European motor vehicle importership in Singapore. He developed the Singapore Audi importership, Premium Automobiles Pte Ltd, where he was the Managing Director for seven years. Ron was then appointed as operation director to further develop a premier Singaporean wellness company, Fabulous Image Lifestyle. He has established a network of business contacts in many areas of enterprise in Asia and Australia. He has contacts in the health sector in Asia as well as associations with businesses and the financial sector in Australia and Asia of value to Optiscan. He is a member of risk committee.
    Mr Robert Cooke Non-Executive ChairmanNon-Executive Director Apr 2021
    Mr Cooke has 40+ year career in the health industry, his experience spans executive leadership of publicly listed and privately owned healthcare companies, and management of private and public hospitals in Australia, Asia and the UK. He is a member of Risk committee.
    Ms Karen Borg Non-Executive Director Jul 2021
    Ms Borg has held senior roles in FTSE 100-250 medical device, technology, consumer products and government services organisations. She was the Chief Executive Officer for Catholic Healthcare Ltd and prior to this was the CEO of Healthdirect and the inaugural CEO of Jobs for NSW. She began her career in consumer goods sector and worked for Goodman Fielder, Nestle and Revlon in global business development and marketing. She holds chairmanship of Risk committee.
    Professor Camile Farah Chief Executive OfficerManaging Director May 2021
    Dr Farah has over 25 years of experience leading transformational change across medtech, life sciences, and academic healthcare. He holds multiple non-executive and advisory roles within the medtech, life sciences and healthcare sectors. He has held CEO, Board, and C-suite roles in medtech and diagnostic companies, driving commercial strategy, capital raising, global market expansion, and regulatory approvals.
    Mr Sean Gardiner Non-Executive Director Jun 2022
    Mr Gardiner worked at Morgan Stanley, where he spent 20 years in equity research across three locations and in seven different roles. He joined the London office, covering European Technology and Conglomerate stocks before, in 2005, moving to lead the EEMEA Telecom Services team. In early 2008, Sean transferred to Dubai to setup and manage the MENA Equity Research team. Sean relocated to Singapore in 2010 to oversee and manage the broader Asian research product as well as roll out ASEAN Real Estate coverage. He is a member of risk committee.
    Ms Elissa Hansen Company Secretary Feb 2025
    -
    Elissa Hansen Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Peters Investments Pty Ltd 235,840,699 28.23%
    HSBC Custody Nominees (Australia) Limited 156,477,921 18.73%
    Ibsen Pty Ltd (Narula Family Set No3 A/C) 38,500,000 4.61%
    Citicorp Nominees Pty Limited 38,456,930 4.60%
    Harech Pty Ltd (Porter Super Fund A/C) 16,659,185 1.99%
    BNP Paribas Noms Pty Ltd 15,374,184 1.84%
    Mr Chris Graham + Mrs Diane Graham (C & D Graham S/F A/C) 12,700,000 1.52%
    Dixson Trust Pty Limited 8,474,270 1.01%
    Camile Farah + Marie Matias (Farah & Matias Family A/C) 8,000,000 0.96%
    BNP Paribas Noms Pty Ltd Uobkh A/C R'Miers 7,377,386 0.88%
    Kebin Nominees Pty Ltd 6,784,479 0.81%
    Mr Kah Chin Lee 5,088,888 0.61%
    Ibsen Pty Ltd (Ibsen Superfund A/C) 5,000,000 0.60%
    Mr Christopher John Martin 4,209,448 0.50%
    Mr Wally Knezevic 4,134,260 0.49%
    Mr Alfred Joseph Winkelmeier + Mrs Christine Edith Winkelmeier <The Winkelmeier S/F A/C> 3,710,000 0.44%
    Semblance Pty Ltd (Graeme Mutton Retire S/Fund) 3,540,000 0.42%
    Sash Pty Ltd (Knezevic Super Fund A/C) (i) 3,515,741 0.42%
    Mr Jubran William Toak + Mr Melhem William Toak 3,422,996 0.41%
    Sash Pty Ltd (Knezevic Super Fund A/C) (ii) 3,422,223 0.41%

    Profile

    since

    Note